Fibrotic skin disorders, such as keloid disease (KD), are common clinically challenging disorders with unknown etiopathogenesis and ill-defined treatment strategies that affect millions of people worldwide. Thus, there is an urgent need to discover novel therapeutics. The validation of potential drug targets is an obligatory step in discovering and developing new therapeutic agents for the successful treatment of dermal fibrotic conditions, such as KD. The integration of multi-omics data with traditional and modern technological approaches, such as RNA interference (RNAi) and genome-editing tools, would provide unique opportunities to identify and validate novel targets in KD during early drug development. Thus, in this review, we summarize the current and emerging drug discovery process with a focus on validation strategies of potential drug targets identified in dermal fibrosis.

纤维化皮肤病，例如瘢痕疙瘩病 (KD)，是常见的具有临床挑战性的疾病，病因不明，治疗策略不明确，影响全球数百万人。因此，迫切需要发现新的治疗方法。潜在药物靶点的验证是发现和开发用于成功治疗皮肤纤维化病症（例如 KD）的新治疗剂的必要步骤。多组学数据与传统和现代技术方法的整合，如 RNA 干扰 (RNAi) 和基因组编辑工具，将为在早期药物开发过程中识别和验证 KD 中的新靶点提供独特的机会。因此，在本次审查中，